908 Devices Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. 908 Devices sells handheld and desktop mass spectrometry instruments and related consumables and services for government, life sciences, bioprocessing, and other markets.
Financial results
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Total revenue | $8.3 million | $5.5 million | +50% |
| Product and service revenue | $8.0 million | $5.4 million | +50% |
| Gross profit | $4.1 million | $2.9 million | +42% |
| Gross margin | 49.7% | 52.5% | Down 2.8 percentage points |
| Operating expenses | $13.7 million | $8.7 million | +57% |
| Operating loss | $9.5 million | $5.8 million | Loss increased |
| Net loss | $9.4 million | $6.1 million | Loss increased |
| Net loss per share, basic and diluted | $0.30 | $0.22 | Loss per share increased |
| Cash used in operating activities | $0.5 million | $9.6 million | Lower cash use |
- Revenue growth reflected higher device sales ($5.5 million, up 41%) and consumables and service revenue ($2.5 million, up 73%). Product placements rose to 83 from 66; cumulative placements reached 2,018 from 1,427.
- Product and service gross margin declined to 50% from 52%, primarily due to higher personnel and facility costs. Operating expenses rose substantially, including SG&A up 69% to $9.7 million and R&D up 32% to $3.9 million. Stock-based compensation was $1.3 million, versus $0.3 million.
- Cash and cash equivalents were $223.1 million at March 31, 2022, down from $224.1 million at year-end. Current assets were $243.0 million and current liabilities $13.7 million. The company reported total liabilities of $44.4 million and stockholders’ equity of $206.8 million.
- Debt was $15.0 million under a $25.0 million revolving facility, due March 2024. The company reported compliance with its covenants, including a $10.0 million minimum unrestricted cash requirement. Q1 financing activity included offsetting $15.0 million revolver draw and repayment.
Changes versus prior year
- Revenue increased $2.8 million, led by desktop device sales, including Rebel, and higher recurring consumables and service revenue. Consumables and service grew to 31% of product and service revenue from 27%.
- Operating loss widened by $3.7 million as operating expense growth exceeded gross profit growth. Net loss widened by $3.3 million.
- Operating cash use improved by $9.2 million, principally reflecting a $10.1 million cash benefit from accounts receivable changes. This was partly offset by increased inventory and lower accounts payable and accrued expenses.
- Cash declined only modestly, while inventory increased to $9.6 million from $7.9 million. Deferred revenue related to product and service increased to $14.8 million from $14.5 million at year-end.
Outlook, commentary, and risks
- Management expects continued operating losses as it invests in sales, manufacturing capacity, research and development, and commercial expansion. It expects R&D and SG&A expenses to increase.
- Management believes cash, cash equivalents, and product and service revenue will fund operating expenses, capital expenditures, and debt service for at least 12 months from issuance of the statements. This is an estimate based on assumptions; the filing gives no specific revenue or earnings guidance.
- COVID-19-related supply-chain lead times, travel limitations, and installation, training, and shipment delays continued into 2022; China lockdowns were also noted. Prolonged disruption could affect manufacturing, customer demand, collections, and results.
- Revenue and receivables are concentrated: one customer represented 17% of Q1 revenue and 21% of gross receivables at quarter-end. Of $2.8 million in EMEA receivables, $1.7 million was more than 90 days past due and covered by an allowance.
- Some product components depend on sole-source, single-source, or limited suppliers. Government sales cycles and order timing can produce period-to-period fluctuations; the company also noted competition, market adoption, and potential need for additional financing as risks.
- The company reported no material legal proceedings and no material changes to the risk factors in its 2021 annual report. Disclosure controls were assessed as effective at a reasonable assurance level.
Key facts for investors to verify
- Whether revenue growth and product placements continue, and how much growth comes from devices versus recurring consumables and services.
- Whether gross margins recover as production scales, given rising operating costs and the Q1 margin decline.
- Cash use and working-capital movements, particularly collections of overdue EMEA receivables and inventory levels.
- Customer and supplier concentration, COVID-related supply impacts, and compliance with revolver covenants.
- Management’s 12-month liquidity estimate against continued losses and planned commercial and R&D investment.